This is a promotional website developed by AstraZeneca and intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk.

 

Resources for you
and your patients

Explore our range of materials that can help support
your understanding of TRUQAP (capivasertib), guide prescribing and
help reassure patients throughout the treatment journey.

aBC=advanced breast cancer; AE=adverse event; AKT1=serine/threonine protein kinase 1; CDK4/6i=cyclin-dependent kinase 4/6 inhibitor; ET=endocrine therapy; HER2=human epidermal growth factor receptor 2; HR+=hormone receptor positive; NGS=next-generation sequencing; PIK3CA=phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PFS=progression-free survival; PTEN=phosphatase and tensin homologue.

GB-68388 | April 2026

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.